QTTB Quote, Financials, Valuation and Earnings

Candel Therapeutics has a net margin of -- compared to Q32 Bio's net margin of --. Q32 Bio's return on equity of -- beat Candel Therapeutics's return on equity of --.

Q32 Bio has a consensus price target of --, signalling upside risk potential of 405.81%. On the other hand Candel Therapeutics has an analysts' consensus of $11.00 which suggests that it could grow by 118.89%. Given that Q32 Bio has higher upside potential than Candel Therapeutics, analysts believe Q32 Bio is more attractive than Candel Therapeutics.

Q32 Bio has a beta of -0.299, which suggesting that the stock is 129.889% less volatile than S&P 500. In comparison Candel Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Q32 Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Candel Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Q32 Bio pays -- of its earnings as a dividend. Candel Therapeutics pays out -- of its earnings as a dividend.

Q32 Bio quarterly revenues are --, which are smaller than Candel Therapeutics quarterly revenues of --. Q32 Bio's net income of -$17.6M is lower than Candel Therapeutics's net income of -$10.6M. Notably, Q32 Bio's price-to-earnings ratio is -- while Candel Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Q32 Bio is -- versus 2,101.24x for Candel Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

ImmunityBio has a net margin of -- compared to Q32 Bio's net margin of -1404.01%. Q32 Bio's return on equity of -- beat ImmunityBio's return on equity of --.

Q32 Bio has a consensus price target of --, signalling upside risk potential of 405.81%. On the other hand ImmunityBio has an analysts' consensus of $14.25 which suggests that it could grow by 456.64%. Given that ImmunityBio has higher upside potential than Q32 Bio, analysts believe ImmunityBio is more attractive than Q32 Bio.

Q32 Bio has a beta of -0.299, which suggesting that the stock is 129.889% less volatile than S&P 500. In comparison ImmunityBio has a beta of 0.741, suggesting its less volatile than the S&P 500 by 25.865%.

Q32 Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ImmunityBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Q32 Bio pays -- of its earnings as a dividend. ImmunityBio pays out -- of its earnings as a dividend.

Q32 Bio quarterly revenues are --, which are smaller than ImmunityBio quarterly revenues of $6.1M. Q32 Bio's net income of -$17.6M is higher than ImmunityBio's net income of -$85.7M. Notably, Q32 Bio's price-to-earnings ratio is -- while ImmunityBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Q32 Bio is -- versus 238.06x for ImmunityBio. Usually stocks with elevated PS ratios are considered overvalued.

Phibro Animal Health has a net margin of -- compared to Q32 Bio's net margin of 2.68%. Q32 Bio's return on equity of -- beat Phibro Animal Health's return on equity of 6.55%.

Q32 Bio has a consensus price target of --, signalling upside risk potential of 405.81%. On the other hand Phibro Animal Health has an analysts' consensus of $19.40 which suggests that it could fall by -7.62%. Given that Q32 Bio has higher upside potential than Phibro Animal Health, analysts believe Q32 Bio is more attractive than Phibro Animal Health.

Q32 Bio has a beta of -0.299, which suggesting that the stock is 129.889% less volatile than S&P 500. In comparison Phibro Animal Health has a beta of 0.527, suggesting its less volatile than the S&P 500 by 47.336%.

Q32 Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Phibro Animal Health offers a yield of 2.29% to investors and pays a quarterly dividend of $0.12 per share. Q32 Bio pays -- of its earnings as a dividend. Phibro Animal Health pays out 804.72% of its earnings as a dividend.

Q32 Bio quarterly revenues are --, which are smaller than Phibro Animal Health quarterly revenues of $260.4M. Q32 Bio's net income of -$17.6M is lower than Phibro Animal Health's net income of $7M. Notably, Q32 Bio's price-to-earnings ratio is -- while Phibro Animal Health's PE ratio is 48.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Q32 Bio is -- versus 0.81x for Phibro Animal Health. Usually stocks with elevated PS ratios are considered overvalued.

Patterson Companies has a net margin of -- compared to Q32 Bio's net margin of 1.6%. Q32 Bio's return on equity of -- beat Patterson Companies's return on equity of 15.7%.

Q32 Bio has a consensus price target of --, signalling upside risk potential of 405.81%. On the other hand Patterson Companies has an analysts' consensus of $29.68 which suggests that it could fall by -3.84%. Given that Q32 Bio has higher upside potential than Patterson Companies, analysts believe Q32 Bio is more attractive than Patterson Companies.

Q32 Bio has a beta of -0.299, which suggesting that the stock is 129.889% less volatile than S&P 500. In comparison Patterson Companies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.422%.

Q32 Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Patterson Companies offers a yield of 3.37% to investors and pays a quarterly dividend of $0.26 per share. Q32 Bio pays -- of its earnings as a dividend. Patterson Companies pays out 52.89% of its earnings as a dividend. Patterson Companies's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Q32 Bio quarterly revenues are --, which are smaller than Patterson Companies quarterly revenues of $1.7B. Q32 Bio's net income of -$17.6M is lower than Patterson Companies's net income of $26.8M. Notably, Q32 Bio's price-to-earnings ratio is -- while Patterson Companies's PE ratio is 18.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Q32 Bio is -- versus 0.42x for Patterson Companies. Usually stocks with elevated PS ratios are considered overvalued.